{"id":542942,"date":"2021-05-12T19:04:01","date_gmt":"2021-05-12T19:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542942"},"modified":"2021-05-12T19:04:01","modified_gmt":"2021-05-12T19:04:01","slug":"rich-insights-into-the-methylmalonic-acidemia-market-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-major-players-in-the-industry","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/rich-insights-into-the-methylmalonic-acidemia-market-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-major-players-in-the-industry_542942.html","title":{"rendered":"Rich Insights into the Methylmalonic Acidemia Market, Epidemiology Segmentation, Treatment Landscape, Pipeline Therapies and Major Players in the Industry"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620792779.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Rich Insights into the Methylmalonic Acidemia Market, Epidemiology Segmentation, Treatment Landscape, Pipeline Therapies and Major Players in the Industry\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620792779.png\" alt=\"Rich Insights into the Methylmalonic Acidemia Market, Epidemiology Segmentation, Treatment Landscape, Pipeline Therapies and Major Players in the Industry\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Methylmalonic Acidemia Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s Methylmalonic Acidemia Report delivers an in-depth understanding of the Methylmalonic Acidemia, historical and forecasted epidemiology, and the Methylmalonic Acidemia market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/f67d2bd519a7d4a707282f5faacbdd0c.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/methylmalonic-acidemia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Methylmalonic Acidemia Report<\/a><\/strong> delivers an in-depth understanding of the Methylmalonic Acidemia, historical and forecasted epidemiology, and the Methylmalonic Acidemia market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some Crucial Highlights from the Methylmalonic Acidemia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the research &ldquo;Systematic literature review and meta-analysis on the epidemiology of Methylmalonic Acidemia (MMA) with an emphasis on MMA caused by methylmalonyl-CoA mutase (mut) deficiency&rdquo; by Alm&aacute;si et al. (2019), the Meta-analysis pooled point estimates of MMA detection rates in Asia-Pacific, Europe, North America, and Middle East and North Africa (MENA) were <strong>0.79, 1.12, 1.22, and 6.04 per 100,000 newborns.<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pipeline therapies in the Methylmalonic Acidemia are <strong>LB-001<\/strong> (LogicBio Therapeutics), <strong>HST5040<\/strong> (HemoShear Therapeutics), and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major players involved in the Methylmalonic Acidemia market are <strong>LogicBio Therapeutics, HemoShear Therapeutics,<\/strong> among others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">For more information request sample @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/methylmalonic-acidemia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Methylmalonic Acidemia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Methylmalonic Acidemia market report <\/strong>covers existing clinical practices, new drugs, individual therapies&#8217; market share, and current and forecasted Methylmalonic Acidemia market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Methylmalonic Acidemia: Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Methylmalonic Acidemia (MMA)<\/strong> is a form of &#8220;metabolic inborn error of metabolism&#8221; that is inherited. The body is unable to adequately digest or break down certain proteins and fats (lipids) from the food eaten in this state.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Decompensation incidents, also known as metabolic crises, result from a build-up of toxic compounds and episodes of severe illness. If a metabolic crisis is not addressed, the patient can experience breathing difficulties, seizures, a stroke, a coma, and even death.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Methylmalonic Acidemia Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Methylmalonic Acidemia Total Incident Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Methylmalonic Acidemia Incident Cases Based on Mutation in Genes<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Methylmalonic Acidemia Treatable Cases<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Methylmalonic Acidemia Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Vitamin B12 responsiveness is the primary treatment for MMA patients. A low-protein diet food plan is another treatment option for the patient. Aside from that, organ transplantation is the most effective and efficient choice.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Methylmalonic Acidemia Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market dynamics of Methylmalonic Acidemia (MMA) are expected to shift in the coming years due to the approval of Carbaglu and a rise in the incidence of MMA, as well as the expected launch of emerging therapies such as LB-001 (LogicBio&#8217;s GeneRide technology) and HST5040 (HemoShear Therapeutics), which are expected to boost the market in the forecasted period (2021-2030).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">To learn more visit, <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Methylmalonic Acidemia Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Methylmalonic Acidemia Pipeline Therapies and Major Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">LB-001: LogicBio Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HST5040: HemoShear Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"84\" \/>\n<col width=\"540\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary of Methylmalonic Acidemia (MMA)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia (MMA): Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disease Background and Overview: Methylmalonic Acidemia (MMA)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia (MMA): Country-Wise Epidemiology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia Epidemiology: United States<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia Epidemiology: EU&ndash;5 Countries<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia Epidemiology: Japan<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Treatments and Medical Practices<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Attribute Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Key Cross Competition<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia (MMA): Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">7MM Methylmalonic Acidemia (MMA): Country-Wise Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">United States Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">EU5 Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Japan Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">23.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Methylmalonic Acidemia: Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">24.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">25.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">26.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Reimbursement and Market Access<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">27.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">28.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">29.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">30.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get in touch with our Business executive @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Methylmalonic Acidemia Market Outlook<\/a><\/strong> to know more&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/argininosuccinic-aciduria-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Argininosuccinic Aciduria (ASA) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get comprehensive historical and forecast analysis of Argininosuccinic Aciduria (ASA) Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Horizon Therapeutics, Acer Therapeutics, Evox Therapeutics, among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=rich-insights-into-the-methylmalonic-acidemia-market-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-major-players-in-the-industry\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=rich-insights-into-the-methylmalonic-acidemia-market-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-major-players-in-the-industry\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Methylmalonic Acidemia Market DelveInsight&#8217;s Methylmalonic Acidemia Report delivers an in-depth understanding of the Methylmalonic Acidemia, historical and forecasted epidemiology, and the Methylmalonic Acidemia market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. DelveInsight&#8217;s &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/rich-insights-into-the-methylmalonic-acidemia-market-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-major-players-in-the-industry_542942.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,443],"tags":[],"class_list":["post-542942","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-Website-Blog"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542942"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542942\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}